Kairos Pharma’s development pipeline targets drug resistance and immune suppression, two critical barriers to effective cancer treatment. The company's flagship program, ENV105, is designed to address ...
Kairos Pharma (KAPA) has selected IBN to spearhead its corporate communications efforts. Kairos Pharma’s development pipeline targets drug resistance and immune suppression, two critical barriers to ...
Patients with oncogenic-driven lung cancer account for approximately 40-50% of the lung cancer population. Oral pills are effective at controlling the disease, but patients are not cured due to the ...